Your AI-Trained Oncology Knowledge Connection!

Video

The Potential Future Impact of CAR T Cell Therapy in Adult ALL

Author(s):

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Bijal Shah, MD H. Lee Moffitt Cancer Center & Research Institute

Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
SHAH
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Julie M. Vose, MD, MBA
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Carrie L. Kitko, MD
Peter Riedell, MD
Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.
Related Content
Image Credit: © Tatiana Shepeleva – stock.adobe.com
March 25th 2025

Low Rates of Late-Onset CAR T-Cell–Related CRS/ICANS Support Shorter AE Monitoring Periods

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Image credit: Nittaya – stock.adobe.co
March 21st 2025

NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant R/R Follicular Lymphoma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Image Credit: © Corona Borealis - stock.adobe.com
March 18th 2025

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia

Orca-T in Hematologic Malignancies
March 17th 2025

Orca-T Improves cGVHD-Free Survival in Advanced Hematologic Malignancies